Molecular Pharmacology Program
The Hedvig Hricak Lab
Research
Professor
Our laboratory is working on establishing phenotypic signatures of cancer using multimodality anatomic and molecular imaging. We also aim to integrate multimodality imaging with anatomic pathology, genomics, and other molecular signatures to gain further insight into comprehensive molecular and anatomic tumor profiling. The goal is to further advance understanding of in vivo tumor biology and tumor heterogeneity (both spacial and temporal). We plan to develop and validate tumor biomarkers that can be used for treatment selection, assessment of treatment response or early detection of treatment resistance. Using advanced computational methods of radiomics and radiogenomics, we are evaluating how multimodality/multiplexing technology can advance our knowledge of tumor phenotypes and their associations with genomic mutations. We are also exploring targeted imaging and targeted therapies to ultimately expand the field of theranostics, which we believe is one of the future paths to precision medicine.
Featured News
Publications Highlights
People
Hedvig Hricak, MD, PhD
Carroll and Milton Petrie Chair
Professor
- Radiologist Hedvig Hricak researches methodologies of molecular imaging of prostate and gynecologic tumors.
- MD, University of Zagreb School of Medicine (Yugoslavia)
- Dr. Med. Sc. Karolinska Institute (Sweden)
- 212-639-7284
- Office Phone
- View physician profile
- Physician profile
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Hedvig Hricak discloses the following relationships and financial interests:
-
iCAD, Inc.
Equity; Fiduciary Role / Position
-
Ion Beam Applications
Fiduciary Role / Position
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].